1月15日，迈尔微视MRDVS正式发布顶视导航相机V1 Pro。作为迈尔微视全新旗舰导航相机，V1 Pro凭借软、硬件双重升级，进一步提升导航精度和易用性，助力移动机器人产品力显著提升。独家硬件 硬核升级 V1 Pro是迈尔微视推出的第二代顶视导航相机，其硬件在第一代导航相机V1的基础上进行了硬核升级。●首款内置算力相机...
Pan Y,Zhang JT,Gao X,et al. Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non - small cell lung cancer patients[J]. Cancer Cell,2023,41(10):1763-1773.e4. 证据水平 2b。 背景 PACIFI...
近日,中国医学科学院血液病医院(中国医学科学院血液学研究所)竺晓凡/阮敏团队在Clinical Cancer Research在线发表了题为Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor ...
EP: 1.Goals of Therapy for Transplant-Ineligible MM EP: 2.Strategies to Monitor Multiple Myeloma EP: 3.Frequency of Measuring Treatment Response in MM Now Viewing EP: 4.MRD Testing in Multiple Myeloma EP: 5.Managing Adequate/Inadequate Treatment Response in MM ...
The assay enables rare-cell detection on a standard Mission Bio Tapestri run by adding (i) an upfront bead-based protocol to enrich for blast cells, (ii) a DNA and protein panel designed for AML MRD diagnosis and treatment, and (iii) a new automated analysis pipeline to evaluate single ...
It's really great that we have both options, CAR T therapies and bispecific antibodies, available for our patients in 2024. Both are highly efficacious; they both have pros and cons. I think that it's nice that we can tailor the therapies according to patient preference and what they could...
November 29th 2024 FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL March 9th 2025 Five Under 5: Top Oncology Videos for the Week of 3/2 March 19th 2024 Revisit the OncLive On Air Episodes From February 2024 March 5th 2025 Ivosidenib/CPX-351 Shows Early Activity and Is Safe ...
Guardant Reveal™ is the first tissue-free minimal residual disease (MRD) test for colorectal cancer. Available for breast & lung cancers. Results in under 10 days
FOR ALMOST 20 YEARS, MRD HAS PROVIDED LIGHTING SOLUTIONS THAT SERVE CORPORATE, ENTERTAINMENT, HOSPITALITY, RETAIL AND OTHER COMMERCIAL INDUSTRIES. FROM NEW CONSTRUCTION TO RETROFITS, MRD CREATES, DEVELOPS, AND EXECUTES TURNKEY SPECIALTY SYSTEMS AND CUSTOM SOLUTIONS WITH THE LATEST TECHNOLOGIES. ...
MRD Technology Opportunities:mrd-partnerships@veracyte.com References Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring Whole genome mutational analysis for tumor-informed ctDNA based MRD surveillance, treatment monitoring and biological characterization of urothelial carcino...